Skip to main content

Table 2 Predictors for first ULT dispensation within 365 days after diagnosis

From: Factors associated with initiation and persistence of urate-lowering therapy

   Predictors for ULT dispensation within 365 days (COX)
% with event Univariate hazard ratio 95% CI Multivariate* hazard ratio 95% CI (with eGFR) Multivariate** hazard ratio 95% CI (with renal disease)
Male (ref) 30.33    
Female 26.39 0.87 (0.79–0.95) 0.87 (0.79–0.97) 0.86(0.78–0 .94)
Age, years
 20–49 (ref) 22.84    
 50–59 23.21 1.03 (0.87–1.22) 0.90 (0.72–1.12) 0.96 (0.81–1.14)
 60–69 30.14 1.38 (1.19–1.59) 0.90 (0.74–1.10) 1.15 (0.99–1.34)
 70–79 34.19 1.61 (1.40–1.86) 0.82 (0.67–1.00) 1.25 (1.07–1.46)
 80– 30.74 1.46 (1.26–1.69) 0.57 (0.46–0.71) 1.03 (0.87–1.21)
Level of education
 ≤9 years (ref) 31.10    
 10–12 years 28.78 0.92(0.83–1.31)   
 >12 years 26.32 0.83(0.73–0.93)   
MCCI
 0 (ref) 23.53    
 1–2 34.20 1.57 (1.44–1.72) 1.29 (1.15–1.45) 1.45 (1.31–1.60)
 >2 38.79 1.91 (1.69–2.15) 1.43 (1.23–1.66) 1.73 (1.51–1.99)
Renal disease
0 (ref) 27.48    
1 40.75 1.67 (1.50–1.87)   1.47 (1.31–1.64)
eGFR >60 mL/min/1.73 m2 “normal kidney function” (ref) 26.56    
eGFR 60–31 mL/min/1.73 m2 “reduced kidney function” 44.33 1.91 (1.73–2.11) 2.11 (1.88–2.37)  
eGFR 30–10 mL/min/1.73 m2 severely reduced kidney function” 44.71 2.01 (1.67–2.41) 2.31 (1.90–2.82)  
eGFR <10 mL/min/1.73 m2 “end-stage kidney failure” 30.77 1.14 (0.43–3.04) 1.17 (0.44–3.12)  
2011, ref     
2012   1.10 (0.99–1.21)   
2013   1.02 (0.92–1.13)   
  1. ULT urate-lowering treatment, CI confidence interval, eGFR estimated glomerular filtration rate, MCCI metabolic cardiovascular comorbidity index
  2. *Adjusted for sex, age, comorbidities and eGFR
  3. **Adjusted for sex, age, comorbidities and renal disease defined by ICD 10 coding